Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Key Takeaways GLP-1 medications are associated with a higher risk of gallstones and gallbladder disease, and FDA labeling for Zepbound and Wegovy lists gallstones and acute cholecystitis as possible risks
The SURPASS-CVOT will compare the effect of tirzepatide versus dulaglutide on major adverse cardiovascular events in patients with type 2 diabetes and increased cardiovascular risk
The brainstem provides another critical site for GLP-1's appetite effects
These ranges serve as starting points
US$ 25.69
![Victoza Lawsuit [2026 Update]](https://www.torhoermanlaw.com/wp-content/uploads/2021/07/Victoza-Lawsuit-Victoza-Lawsuit-Overview-Torhoerman-Law.jpg)
US$ 28.50
US$ 24.66
US$ 22.36
US$ 21.03
